BASEL, Switzerland, Dec. 15, 2016 /PRNewswire/ -- Roivant Sciences Ltd., a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives of patients and their families, today announced the opening of Roivant Sciences GmbH as its new global headquarters in Basel, Switzerland.
"Roivant's mission is to reduce the time and cost of developing new medicines for patients," stated Vivek Ramaswamy, founder of the Roivant group of companies. "We believe this location in the hub of European pharmaceutical innovation and talent will support our vision."
Roivant Sciences GmbH will continue to pursue innovative drug development in neurology, oncology, endocrinology, dermatology, and hepatology, while also embracing new therapeutic areas. Several affiliates of Roivant Sciences have opened headquarters in Basel simultaneously including Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia. Axovant Sciences GmbH will manage the company's global pharmaceutical development and commercial activities.
"Axovant is planning for the potential launch of multiple products for patients with dementia including intepirdine, an investigational drug candidate which could become the first new chemical entity approved for Alzheimer's disease in over a decade," said Mark Altmeyer, President and Chief Commercial Officer of Axovant Sciences GmbH. "In anticipation of that exciting opportunity, we are establishing our global headquarters in Basel and intend to build a fully integrated organization to manage global commercial and medical strategies, manufacturing and supply chain, intellectual property, and other business functions. Our presence in Basel will provide access to a high-quality talent pool that will be key to our future success."
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates with the potential to improve the lives of patients and their families. Roivant's mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system.
Roivant delivers R&D solutions to its industry partners by helping them unlock value from their pipelines and realize the full potential of their research by completing the product development cycle. Roivant's clinical development pipeline spans multiple therapeutic areas through strategic alliances, collaborations, and partnerships with academic institutions and pharmaceutical companies, including Takeda Pharmaceuticals, Eisai, GlaxoSmithKline, Vertex Pharmaceuticals, Duke University, and Cincinnati Children's Hospital.
For additional information, visit www.roivant.com.
About Axovant Sciences
Axovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional, and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.
For additional information, visit www.axovant.com.
This press release contains forward-looking statements, including statements regarding Axovant's clinical development, regulatory and commercial strategy, including for intepirdine. Forward-looking statements can be identified by the words "believe," "anticipate," "continue", "estimate", "project," "expect," "plan," "potential," "intends," "will," "would", "could", "should" or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates, including intepirdine and nelotanserin; and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant's views of the clinical study data. The products discussed are investigational and not approved and there can be no assurance that the clinical programs, including those for intepirdine or nelotanserin will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our product candidates will ever receive regulatory approval or be successfully commercialized. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see the "Risk Factors" section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2016, and other filings that Axovant makes with the SEC from time to time. These forward-looking statements are based on information available to Axovant as of the date of this press release and speak only as of the date of this release. Axovant disclaims any obligation to update these forward-looking statements, except as may be required by law.
SOURCE Roivant Sciences Ltd.